In The News
Stay up to date with Dr. Quay
Atossa Therapeutics Announces Successful In vitro Testing Results of COVID-19 Drug: AT-H201 Inhibits SARS-CoV-2 Infectivity of VERO Cells in Laboratory Culture
May 22, 2020
Results Support Development of AT-H201 for COVID-19 Patients
Atossa Therapeutics Contracts with NYC Health + Hospitals/Metropolitan for COVID-19 HOPE Clinical Study
April 27, 2020
Study Designed to Evaluate Atossa’s Combination Therapy AT-H201 to Reduce Patient Time on a Ventilator
Atossa Therapeutics Seeks Clinical Investigation Approval from FDA to Launch the COVID-19 HOPE Study
April 20, 2020
The COVID-19 HOPE trial is the first pharmaceutical study to address getting patients off mechanical ventilator and reducing
COVID-19 “Cease Fire” for the United States on April 23, 2020 and successful ‘Opening Up America Again’ initiative predicted
April 17, 2020
U.S. Physician Scientist Dr. Steven Quay, MD, PhD offers his predictions based on COVID-19 case growth model and firsthand eye witness to Taiwan’s coronavirus best practice policies, many of which are mirrored in the U.S. Administration’s policies
Dr. Quay to attend FDA Virtual Town Hall on COVID-19 testing
March 27, 2020
“I will be attending this workshop on COVID-19 diagnostic testing and will provide a blog if there is something new and relevant”,: said Dr. Steven Quay, MD, PhD. Please stay tuned here.
